论文部分内容阅读
目的观察Ⅲ～Ⅳ级胶质瘤组织中O6甲基鸟嘌呤-DNA甲基转移酶(MGMT)、拓扑异构酶Ⅱα(TopoⅡα)和P-糖蛋白(P-gp)的表达变化,并探讨其意义。方法采用免疫组织化学法检测36例Ⅲ～Ⅳ级胶质瘤、24例Ⅰ～Ⅱ级胶质瘤及10例正常脑组织中的MGMT、TopoⅡα及P-gp。结果高级别胶质瘤组织中MGMT、TopoⅡα、P-gp阳性率分别为72.2%、50.0%、66.7%,Ⅰ～Ⅱ级胶质瘤中分别为29.2%、33.3%、25.0%,正常脑组织中分别为10%、0、0,三者两两比较,P均<0.01。相关分析表明,Ⅲ～Ⅳ级胶质瘤组织中MGMT与P-gp、TopoⅡα与P-gp有关,r分别为0.444、0.478。结论高级别胶质瘤中MGMT、TopoⅡα、P-gp表达增高,可根据其表达情况制定个体化的化疗方案。
Objective To investigate the expression changes of O6-methylguanine-DNA methyltransferase (MGMT), TopoⅡα and P-gp in grade Ⅲ-Ⅳ glioma Its meaning. Methods Immunohistochemical method was used to detect MGMT, TopoⅡα and P-gp in 36 cases of grade Ⅲ-Ⅳ gliomas, 24 grade Ⅰ-Ⅱ gliomas and 10 cases of normal brain tissues. Results The positive rates of MGMT, TopoⅡα and P-gp in high-grade gliomas were 72.2%, 50.0% and 66.7% respectively, and in grade Ⅰ-Ⅱ gliomas, they were 29.2%, 33.3% and 25.0% In 10%, 0,0, respectively, comparing the three, each P <0.01. Correlation analysis showed that MGMT was associated with P-gp, TopoⅡα and P-gp in grade Ⅲ-Ⅳ gliomas with r values of 0.444 and 0.478, respectively. Conclusion The expression of MGMT, TopoⅡα and P-gp in high-grade gliomas is increased, and individualized chemotherapy regimens can be formulated according to their expression.